Gilead agreed to acquire Sprint Bioscience’s preclinical TREX1 cancer program for an upfront payment reported at $14 million and potential milestone payments totaling up to $400 million. The deal gives Gilead a TREX1‑targeting asset aimed at exploiting tumor immunology pathways and augments its oncology pipeline. Gilead has been expanding oncology R&D through targeted acquisitions; this buy reflects a strategy of buying early‑stage, mechanism‑driven programs with high upside. Sprint’s TREX1 asset was positioned as a novel approach to modulate tumor DNA sensing and antitumor immunity. Developers and investors will watch how Gilead integrates the program and funds IND‑enabling work, and whether TREX1 modulation delivers a differentiated clinical benefit when combined with existing immunotherapies.